BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Dranitsaris G, Cohen RB, Acton G, Keltner L, Price M, Amir E, Podack ER, Schreiber TH. Statistical Considerations in Clinical Trial Design of Immunotherapeutic Cancer Agents. J Immunother 2015;38:259-66. [PMID: 26261889 DOI: 10.1097/CJI.0000000000000089] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
Number Citing Articles
1 Smare C, Lakhdari K, Doan J, Posnett J, Johal S. Evaluating Partitioned Survival and Markov Decision-Analytic Modeling Approaches for Use in Cost-Effectiveness Analysis: Estimating and Comparing Survival Outcomes. Pharmacoeconomics 2020;38:97-108. [PMID: 31741315 DOI: 10.1007/s40273-019-00845-x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
2 Karlsson AK, Saleh SN. Checkpoint inhibitors for malignant melanoma: a systematic review and meta-analysis. Clin Cosmet Investig Dermatol 2017;10:325-39. [PMID: 28883738 DOI: 10.2147/CCID.S120877] [Cited by in Crossref: 37] [Cited by in F6Publishing: 22] [Article Influence: 7.4] [Reference Citation Analysis]
3 Freeman SC, Cooper NJ, Sutton AJ, Crowther MJ, Carpenter JR, Hawkins N. Challenges of modelling approaches for network meta-analysis of time-to-event outcomes in the presence of non-proportional hazards to aid decision making: Application to a melanoma network. Stat Methods Med Res 2022;:9622802211070253. [PMID: 35044255 DOI: 10.1177/09622802211070253] [Reference Citation Analysis]
4 Martin Lluesma S, Wolfer A, Harari A, Kandalaft LE. Cancer Vaccines in Ovarian Cancer: How Can We Improve? Biomedicines 2016;4:E10. [PMID: 28536377 DOI: 10.3390/biomedicines4020010] [Cited by in Crossref: 33] [Cited by in F6Publishing: 28] [Article Influence: 5.5] [Reference Citation Analysis]